Range Low Price High Price Comment
30 days $10.11 $12.52 Wednesday, 1st May 2024 KALV stock ended at $12.18. This is 7.31% more than the trading day before Tuesday, 30th Apr 2024. During the day the stock fluctuated 10.31% from a day low at $11.35 to a day high of $12.52.
90 days $10.11 $16.88
52 weeks $7.21 $16.88

Historical KalVista Pharmaceuticals Inc prices

Date Open High Low Close Volume
Feb 20, 2024 $14.60 $14.78 $13.63 $13.80 1 382 499
Feb 16, 2024 $14.66 $15.00 $14.31 $14.86 1 205 491
Feb 15, 2024 $16.08 $16.88 $14.65 $14.76 7 188 857
Feb 14, 2024 $14.95 $15.23 $14.37 $14.40 1 557 682
Feb 13, 2024 $15.84 $16.13 $13.26 $14.85 4 454 980
Feb 12, 2024 $16.04 $16.40 $15.80 $16.04 448 234
Feb 09, 2024 $15.47 $16.24 $15.30 $16.00 445 233
Feb 08, 2024 $14.48 $14.91 $14.35 $14.90 436 107
Feb 07, 2024 $14.79 $14.98 $14.31 $14.45 662 889
Feb 06, 2024 $15.72 $16.11 $14.71 $14.83 507 340
Feb 05, 2024 $15.20 $16.12 $15.01 $15.85 406 259
Feb 02, 2024 $15.56 $16.08 $15.09 $15.22 627 464
Feb 01, 2024 $15.81 $16.87 $15.41 $15.74 895 402
Jan 31, 2024 $14.76 $16.20 $14.54 $15.77 914 244
Jan 30, 2024 $14.39 $14.94 $14.15 $14.81 863 398
Jan 29, 2024 $13.40 $14.53 $13.17 $14.33 627 687
Jan 26, 2024 $12.85 $13.47 $12.81 $13.37 506 560
Jan 25, 2024 $12.50 $13.11 $12.50 $12.85 273 237
Jan 24, 2024 $12.64 $12.64 $12.00 $12.16 208 058
Jan 23, 2024 $13.05 $13.07 $12.37 $12.51 207 053
Jan 22, 2024 $12.67 $13.11 $12.38 $12.99 376 079
Jan 19, 2024 $12.47 $12.59 $12.24 $12.41 181 787
Jan 18, 2024 $13.05 $13.05 $12.39 $12.46 222 746
Jan 17, 2024 $12.71 $13.16 $12.25 $13.00 444 562
Jan 16, 2024 $12.98 $13.09 $12.53 $12.83 313 952
Click to get the best stock tips daily for free!

About KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed ... KALV Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT